The global large and small-scale bioprocessing market revenue was around US$ 57.08 billion in 2022 and is estimated to reach US$ 185.5 billion by 2031, growing at a compound annual growth rate (CAGR) of 14% during the forecast period from 2023 to 2031.
Large-scale bioprocessing involves the industrial-scale production of bioproducts and biopharmaceuticals to meet the demands of a wide patient population. It operates bioreactors with capacities in the thousands to tens of thousands of liters and prioritizes efficiency, cost-effectiveness, and automation. Large-scale bioprocessing is necessary for the mass production of well-established biopharmaceuticals, such as monoclonal and vaccine antibodies.
Small-scale bioprocessing occurs at laboratory or pilot-scale levels, utilizing bioreactors with fewer volumes, typically ranging from rare liters to a few hundred liters. It is mainly employed in development, research, and process optimization stages, resource efficiency, offering flexibility, and a platform for innovation. Successful findings in small-scale processes can inform and enhance large-scale production, making it an important component of bioprocess development.
Market Driving Factors
Increasing demand for generic biologics, biosimilars, and personalized medicine drives the market growth. This is mainly due to the expiration of patents on biologic drugs, which has significantly impacted large-scale bioprocessing. In addition, biosimilars and generic biologics aim to offer more reasonable options for biologic drugs, making them more accessible to patients. Large-scale bioprocessing facilities are needed to create these biologics efficiently and cost-effectively to meet this growing demand
Advancements in bioprocessing technologies boost the market growth. This is primarily due to the ongoing advancements in bioprocessing equipment, automation, and analytics that enhance the scalability and efficiency of large-scale production. In addition, single-use bioprocessing systems and equipment have become increasingly popular in large-scale bioprocessing. These systems eliminate the requirement for cleaning and sterilization, lowering downtime and contamination risk.
Regulatory compliance is a substantial challenge in large and small-scale bioprocessing markets.
Regional Analysis
North America dominated the market in terms of the largest share. This can be mainly attributed to the increase biopharmaceutical sector and advanced technology. The region, led by the United States, major biotech and pharmaceutical players, surged demand for cutting-edge bioprocessing. In addition, constant research and development efforts drive innovation, resulting in enhanced single-use systems, analytical tools, and bioreactors. As a result, strict regulatory standards ensure top-notch facilities, maintaining a competitive edge.
Asia Pacific is expected to experience substantial growth during the forecast period. This is mainly due to the biotechnology and pharmaceutical sectors are rapidly rising. These sectors creating an increasing requirement for bioprocessing solutions in drug development and manufacturing. In addition, significant investments in bioprocessing infrastructure, coupled with a professional and educated workforce, improve the region’s abilities.
Furthermore, continuous research and development efforts, regulatory advancements, and global partnerships contribute to technological innovation and global collaboration. Moreover, government support and incentives also promote industry growth, while the increasing demand for cutting-edge healthcare solutions owing to surging population positions in the region.
Segmentation Insights
Product Insight
The bioreactors/fermenters segment is estimated to dominate the market in terms of the largest market share. Bioreactors are crucial in the production of biopharmaceuticals, including monoclonal antibodies and vaccines, responding to global healthcare needs. Additionally, constant innovations in bioprocessing techniques and bioreactor design improve scalability and efficiency, making them indispensable for a multitude of applications. Moreover, the emergence of biotechnology startups increases innovation, creating possibilities for new bioprocesses and boosting the demand for bioreactors.
The cell culture product segment is expected to be the fastest-growing in the market. This is due to the continuous advancements in cell line development, including the development of the recombinant cell line. One of the most important applications of cell culture in molecular and cell biology is to offer a platform for studying the biochemical, biological, physiological, and metabolic systems of wild-type and sick cells. Thus, the production of biopharmaceutical-derived cell lines from mammalian cell lines supports segment growth
Scale Insight
The industrial scale segment dominated the market in terms of the largest revenue. The demand for biopharmaceuticals, particularly vaccines and monoclonal antibodies, has increased the expansion of biomanufacturing processes. Advancements in bioprocessing technology and bioreactor design have improved scalability and efficiency, while the increase in biotech startups fosters innovation.
Furthermore, the growth of industrial-scale bioprocessing has been attributed to various factors such as technological integration, food and beverage production, regulatory compliance, sustainability considerations, the biofuel sector, and the expansion of the large and small-scale bioprocessing markets. These factors support the important role that bioprocessing plays in producing a variety of bioproducts.
Application Insight
The biopharmaceuticals segment dominates the market in terms of the substantial share. Large-scale bioprocessing entails the high-volume production of biopharmaceuticals using huge bioreactors, cutting-edge automation, and rigorous quality control. It benefits from economies of scale and is necessary for fulfilling the demands of a broad patient population.
In addition, small-scale bioprocessing is used in research and development, using smaller bioreactors for process optimization, flexibility, and decreased resource requirements. It allows for customization, simultaneous evaluation of numerous conditions, and the exploration of different biopharmaceuticals. Therefore, successful small-scale processes inform and optimize large-scale production, providing the quality and availability of biopharmaceuticals while lowering resource consumption.
Prominent Companies
Segmentation Outline
The global large and small-scale bioprocessing market segmentation focuses on Product, Workflow, Scale, Application, and Region.
By Product
By Workflow
By Scale
By Application
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: LARGE AND SMALL-SCALE BIOPROCESSING MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 FILTRATION ASSEMBLIES
5.3 BIOREACTORS/FERMENTERS
5.4 CELL CULTURE PRODUCTS
5.5 OTHERS
6 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET, BY WORKFLOW
6.1 OVERVIEW
6.2 DOWNSTREAM PROCESSING
6.3 FERMENTATION
6.4 UPSTREAM PROCESSING
7 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET, BY SCALE
7.1 OVERVIEW
7.2 SMALL SCALE
7.3 INDUSTRIAL SCALE
8 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 ENVIRONMENTAL AIDS
8.3 BIOPHARMACEUTICALS
8.4 SPECIALITY INDUSTRIAL CHEMICALS
8.5 OTHERS
9 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL LARGE AND SMALL-SCALE BIOPROCESSING MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 AB SCIEX
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 ABEC
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 BOEHRINGER INGELHEIM
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 BRAMMER BIO
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 CELLGENIX
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 DANAHER CORPORATION
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 EPPENDORF AG
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 GENERAL ELECTRIC (GE) HEALTHCARE
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 LONZA GROUP
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 MERCK & CO., INC
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.12 MILLIPORESIGMA
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.13 NOVASEP
11.13.1 OVERVIEW
11.13.2 FINANCIAL PERFORMANCE
11.13.3 PRODUCT OUTLOOK
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.14 PALL CORPORATION
11.14.1 OVERVIEW
11.14.2 FINANCIAL PERFORMANCE
11.14.3 PRODUCT OUTLOOK
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.15 THERMO FISHER SCIENTIFIC
11.15.1 OVERVIEW
11.15.2 FINANCIAL PERFORMANCE
11.15.3 PRODUCT OUTLOOK
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved